Celyad Oncology SA logo

Celyad Oncology SA

XBRU:CYAD (Belgium)  
€ 0.30 (-3.06%) May 24
At Loss
P/B:
7.08
Market Cap:
€ 12.45M ($ 13.51M)
Enterprise V:
€ 8.01M ($ 8.69M)
Volume:
7.14K
Avg Vol (2M):
15.21K
Also Trade In:
Volume:
7.14K
At Loss

Business Description

Description
Celyad Oncology SA is a biopharmaceutical company focused on the discovery and development of innovative technologies for chimeric antigen receptor T-cell (CAR T) therapies. The company focuses on solid tumors and hematological malignancies. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks including CELYAD, C-CATH, C_CURE, CAR-T Cell, THINK, CYAD01 - Deplethink, CYAD02 - Cycle1, CwalityCAR, CYAD-101, and new engagers. The firm has Cardiology and Immuno-oncology operating segments. It generates majority of its revenue from Cardiology segment.
Name Current Vs Industry Vs History
Cash-To-Debt 9.28
Equity-to-Asset 0.08
Debt-to-Equity 0.53
Debt-to-EBITDA -0.04
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 41.59
9-Day RSI 43.61
14-Day RSI 43.82
6-1 Month Momentum % -36
12-1 Month Momentum % -38.93

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 1.26
Quick Ratio 1.26
Cash Ratio 0.82

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -17.5
Shareholder Yield % 16.32

Profitability Rank

Name Current Vs Industry Vs History
ROE % -117.18
ROA % -44.37
ROIC % -71.91
ROC (Joel Greenblatt) % -1041.55
ROCE % -62.22

GF Value Rank

Name Current Vs Industry Vs History
PB Ratio 7.08
Price-to-Tangible-Book 15.03
EV-to-EBIT -0.56
EV-to-EBITDA -0.56
EV-to-FCF -0.3
Earnings Yield (Greenblatt) % -174.96
FCF Yield % -225.98

Financials (Next Earnings Date:2024-08-02 Est.)

XBRU:CYAD's 30-Y Financials
Income Statement Breakdown FY
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Celyad Oncology SA Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil €)
EPS (TTM) (€) -0.62
Beta 2.09
Volatility % 64.74
14-Day RSI 43.82
14-Day ATR (€) 0.018738
20-Day SMA (€) 0.310975
12-1 Month Momentum % -38.93
52-Week Range (€) 0.29 - 1.28
Shares Outstanding (Mil) 41.43

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Celyad Oncology SA Filings

Filing Date Document Date Form
No Filing Data

Celyad Oncology SA Stock Events

Financials Calendars
Event Date Price(€)
No Event Data

Celyad Oncology SA Frequently Asked Questions

What is Celyad Oncology SA(XBRU:CYAD)'s stock price today?
The current price of XBRU:CYAD is €0.30. The 52 week high of XBRU:CYAD is €1.28 and 52 week low is €0.29.
When is next earnings date of Celyad Oncology SA(XBRU:CYAD)?
The next earnings date of Celyad Oncology SA(XBRU:CYAD) is 2024-08-02 Est..
Does Celyad Oncology SA(XBRU:CYAD) pay dividends? If so, how much?
Celyad Oncology SA(XBRU:CYAD) does not pay dividend.

Press Release

Subject Date
No Press Release